These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 28625005)
41. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577 [TBL] [Abstract][Full Text] [Related]
42. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer. Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893 [TBL] [Abstract][Full Text] [Related]
43. [Effectiveness of neoadjuvant chemotherapy for the patients with locally invasive bladder cancer]. Noguchi S; Takase K; Yoshida M; Yumura Y; Yamashita Y; Oogo Y; Miyoshi Y Nihon Hinyokika Gakkai Zasshi; 2005 Jul; 96(5):548-53. PubMed ID: 16083032 [TBL] [Abstract][Full Text] [Related]
44. Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy. Faiena I; Salmasi A; Mendhiratta N; Lenis AT; Pooli A; Drakaki A; Gollapudi K; Blumberg J; Pantuck AJ; Chamie K World J Urol; 2018 Nov; 36(11):1825-1833. PubMed ID: 29752514 [TBL] [Abstract][Full Text] [Related]
45. Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. Foerster B; Abufaraj M; Petros F; Azizi M; Gupta M; Schweitzer D; Margulis V; Iwata T; Kimura S; Shabsigh A; Briganti A; Ku JH; Muilwijk T; Kassouf W; Matin SF; Spiess PE; Pierorazio PM; Hendricksen K; Shariat SF; J Urol; 2020 Jun; 203(6):1101-1108. PubMed ID: 31898919 [TBL] [Abstract][Full Text] [Related]
46. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma. Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183 [TBL] [Abstract][Full Text] [Related]
47. Can patient selection for bladder preservation be based on response to chemotherapy? Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521 [TBL] [Abstract][Full Text] [Related]
48. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036 [TBL] [Abstract][Full Text] [Related]
49. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. Zargar-Shoshtari K; Sverrisson EF; Sharma P; Gupta S; Poch MA; Pow-Sang JM; Spiess PE; Sexton WJ Clin Genitourin Cancer; 2016 Feb; 14(1):82-8. PubMed ID: 26411593 [TBL] [Abstract][Full Text] [Related]
50. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin. van de Putte EE; Mertens LS; Meijer RP; van der Heijden MS; Bex A; van der Poel HG; Kerst JM; Bergman AM; Horenblas S; van Rhijn BW World J Urol; 2016 Feb; 34(2):157-62. PubMed ID: 26184106 [TBL] [Abstract][Full Text] [Related]
51. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). Scosyrev E; Ely BW; Messing EM; Speights VO; Grossman HB; Wood DP; de Vere White RW; Vogelzang NJ; Trump DL; Natale RB; Tangen CM; Crawford ED; Thompson IM BJU Int; 2011 Sep; 108(5):693-9. PubMed ID: 21105991 [TBL] [Abstract][Full Text] [Related]
52. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer. Necchi A; Mariani L; Giannatempo P; Raggi D; Farè E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Pizzocaro G; De Braud FG; Gianni AM; Salvioni R Clin Genitourin Cancer; 2014 Jun; 12(3):203-209.e1. PubMed ID: 24394493 [TBL] [Abstract][Full Text] [Related]
53. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study. Hermans TJ; Fransen van de Putte EE; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; de Wit R; Beerepoot LV; Verhoeven RH; van Rhijn BW Eur J Cancer; 2016 Dec; 69():1-8. PubMed ID: 27814469 [TBL] [Abstract][Full Text] [Related]
54. Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder. Hensley PJ; Goodwin J; Davenport DL; Strup SE; James A Clin Genitourin Cancer; 2018 Aug; 16(4):e851-e858. PubMed ID: 29548614 [TBL] [Abstract][Full Text] [Related]
55. Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy. Masson-Lecomte A; Xylinas E; Bouquot M; Sibony M; Allory Y; Comperat E; Zerbib M; de la Taille A; Rouprêt M World J Urol; 2015 Aug; 33(8):1087-93. PubMed ID: 25179011 [TBL] [Abstract][Full Text] [Related]
56. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial. Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822 [TBL] [Abstract][Full Text] [Related]
57. Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. von Rundstedt FC; Mata DA; Groshen S; Stein JP; Skinner DG; Stadler WM; Cote RJ; Kryvenko ON; Godoy G; Lerner SP BJU Int; 2015 Jul; 116(1):44-9. PubMed ID: 25413313 [TBL] [Abstract][Full Text] [Related]
58. [Neoadjuvant chemotherapy in advanced-stage bladder carcinoma. A randomized prospective study comparing MVAC and MVEEC]. Monica B; Larosa M; Frattini A; Macaluso G; Cocconi G; Passalacqua R; Leonardi F Arch Ital Urol Androl; 1994 Dec; 66(5):235-43. PubMed ID: 7812302 [TBL] [Abstract][Full Text] [Related]
59. [Neoadjuvant chemotherapy (M-VAC) in invasive cancer of the bladder. Our experience]. González Enguita C; Caro Cebrián C; Roncalés Badal A; Gil Sanz MJ; Martínez Bengoechea J; Rioja Sanz LA Arch Esp Urol; 1990; 43 Suppl 2():197-204. PubMed ID: 2096779 [TBL] [Abstract][Full Text] [Related]
60. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. D'Andrea D; Matin S; Black PC; Petros FG; Zargar H; Dinney CP; Cookson MS; Kassouf W; Dall'Era MA; McGrath JS; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; Sridhar SS; North S; Barocas DA; Lotan Y; Stephenson AJ; van Rhijn BW; Spiess PE; Daneshmand S; Shariat SF BJU Int; 2021 May; 127(5):528-537. PubMed ID: 32981193 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]